About

About Image

      About

      Bone Biologics is a publicly traded company based in Boston, MA and is focused on developing and marketing orthobiologic products. Our proprietary platform technology is NELL-1, a recombinant human protein growth factor that is essential for normal bone development. Our lead product is a NELL-1 based bone graft substitute for spine fusion, targeting the rapidly growing orthobiologics market. Our goal is to offer patients superior safety with uncompromising efficacy relative to existing technologies. NELL-1  provides specific targeted regulation over bone regeneration in the presence of targeted osteogenic cells, as both demonstrated in the lab and through the use of animal testing, unlike any other current therapy. It has been shown not to form bone when applied to non-osteogenic cells such as myoblasts (a type of embryonic progenitor cell that differentiates to give rise to muscle cells) nor does it induce adipogenesis (the formation of fat that can occur within the bone matrix often exhibited as cysts) that results in weaker bone.

      MISSION
      Our mission is to utilize the power of NELL-1 to improve clinical outcomes and reduce total health care delivery costs associated with spinal fusion. Bone Biologics is focused on bone repair and regeneration applications and is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

      Leadership

      Leadership Image

          Management Team

          LaNeveBioImage

          Stephen R. La Neve, Chief Executive Officer and President
          Stephen R. La Neve has served as our Chief Executive Officer and President since August 17, 2015. He brings thirty years of health care experience, leadership and success to Bone Biologics Inc. Prior to his current position, La Neve held leadership roles in the device and diagnostic segments which include: CEO and president of Etex Corporation; president of Becton Dickinson’s Pre-Analytical Systems business; president of Medtronic’s $3.5b Spine and Biologics business; and president of Medtronic’s second largest country business unit, Medtronic Japan. He also served as senior vice president and executive vice president at Premier, one of the largest GPOs in the United States and ran the global Injection Systems business unit for Becton Dickinson. Additionally, La Neve has held a number of commercial leadership roles at Becton Dickinson, Roche Diagnostics and E Merck Diagnostic Systems in sales, marketing, strategic planning and project management both in the US and outside the US. He serves on the board of directors for Bone Biologics, SkelRegen, LLC and Rapid Pathogen Screening, Inc. (RPS), and he consults for private equity companies in the medical device area. La Neve earned a B.S. in Health Planning and Administration from the Pennsylvania State University, an M.B.A. from West Chester University, and is a member of the omicron delta epsilon honor society for academic excellence in economics.

           

          FrelickBioImage

          Jeff Frelick, Chief Operating Officer
          Jeffrey Frelick has served as the Chief Operating Officer of Bone Biologics Inc. since August 2015. Frelick brings more than 25 years of med-tech experience to the position. He spent the past 15 years on Wall Street as a sell-side analyst following the med-tech industry at investment banks such as Canaccord Genuity, ThinkEquity and Lazard. Prior to becoming an equity research analyst, Frelick worked at Boston Biomedical Consultants where he provided strategic planning assistance, market research data and due diligence for diagnostics companies. He previously held sales and sales management positions at Becton Dickinson’s Primary Care Diagnostic Division after gaining technical experience as a laboratory technologist with Clinical Pathology Facility. Frelick earned a B.S. in Biology from the University of Pittsburgh and an M.B.A. from Suffolk University’s Sawyer Business School.

           

          Deina-Walsh

          Deina Walsh, Chief Financial Officer
          Deina Walsh was appointed CFO of Bone Biologics in October 2014. Walsh is a certified public accountant and owner/founder of DHW CPA, PLLC a Public Companies Accounting Oversight Board (PCAOB) registered firm since 2014. Prior to forming her firm, Walsh spent 13 years at a public accounting firm where she was actively responsible for leading firm audit engagements of publicly held entities in accordance with PCAOB standards and compliance with SEC regulations, including internal control requirements under section 404 of the Sarbanes-Oxley Act. Her experience includes work with start-up companies and well-established operating entities. She has assisted many entities seeking debt and equity capital. Areas of specialty include mergers, acquisitions, reverse mergers, consolidations, complex equity structures, foreign currency translations and revenue recognition complexities. Walsh earned an A.S. in Business Administration from Monroe Community College and a B.S. in Accounting from the State University of New York at Brockport.

           

          BodenBioImageScott D. Boden, MD, Chief Medical Advisor
          Dr. Scott Boden is the Chief Medical Advisor of Bone Biologics. He is also a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. Dr. Boden also serves as the Clinical Director of the Whitesides Orthopaedic Research Laboratory and has received many awards, authored over 175 peer-reviewed articles on spine and basic science topics, as well as 30 chapters and 7 textbooks. He is Co-Editor of Seminars in Spine Surgery, a Deputy Editor of SPINE, and a reviewer for The Journal of Bone and Joint Surgery, The Journal of Bone and Mineral Research, and the European Spine Journal.  Dr. Boden served as President and Secretary and President of the American Orthopaedic Association. He received his B.A. and M.D. from the University of Pennsylvania and completed an Orthopaedic Residency at The George Washington University Medical Center, followed by a Spine Fellowship at Case Western Reserve University Hospitals.

          Products

          Products Image

              Products

              While Bone Biologics has chosen to focus its initial product development efforts in spinal fusion, we believe that this regenerative medicine technology has potential in the broader fields of bone regeneration and repair including osteoporosis, chondrocytes and applications using mesenchymal stem cells.

               

              Investor Relations

              Investor Relations Image

                  Investor Relations

                  Bone Biologics was founded in 2004 by Dr. Chia Soo, MD/Vice-Chair and Professor, UCLA Hospital Dept of Orthopedic Surgery; Dr. Kang Ting DMD, DMSc/Professor, UCLA Dental School; and Dr. Benjamin Wu, DDS, PhD/Chair and Professor, UCLA Dept of Bioengineering.The Company was acquired in 2006 by MTF, the major shareholder and primary funder since the acquisition.

                  Headquartered in Boston, Massachusetts, USA, Bone Biologics became a public company in September 2014 and is focused on bone repair and regeneration applications. The company is committed to exploring additional applications of the NELL-1 technology to enhance bone regeneration and repair in areas where the current options provide suboptimal patient outcomes.

                  Contact

                  Contact Image

                      Contact

                      General Inquiries:
                      Chris Martin
                      412.749.9299 x2
                      Chris@AtlasStories.com

                      Investor Inquiries:
                      Mark Collinson
                      714.222.5161
                      mcollinson@compass-ir.com

                      Media Inquiries:
                      Tracy Williams
                      310.824.9000 x22
                      tracy@olmsteadwilliams.com

                      For information regarding our company and/or products, please complete the form below.





                      Your Name (required)

                      Organization

                      Title

                      Email (required)

                      Phone

                      Preferred Means of Reply

                      Your Message

                      Scratch Pad
                      Parent : leadership 6